Aptus Pharma Ltd (APPL) Share Price & Fundamentals

What we do

Aptus Pharma Ltd markets and distributes finished pharmaceutical formulations, operating through contract manufacturing across diverse therapeutic categories.

Founded in

2,010

Market share

Strong presence in Gujarat and West Bengal with plans for pan-India expansion and entry into global markets.

Problem solved

Provides high-quality, reliable pharmaceutical products addressing acute and chronic therapeutic needs with comprehensive dosage forms.

Top clients or who we serve

Serves healthcare professionals and distributors; B2B focus through pharmaceutical channel partners nationwide.

Key management

Includes Managing Director Tejash Maheshchandra Hathi with 20+ years pharmaceutical experience and specialized independent directors.

Our journey and innovations

Started with 25 products in 2013, expanded to 175+ by 2024, establishing 3 divisions: Acute, Chronic, and OTC.

Where we operate

Primarily Gujarat and West Bengal with plans for pan-India growth and international markets in semi-regulated countries.

Top products or what we offer

Offers 175+ products including anti-infectives, gastrointestinal, cardiology, neuropsychiatric, wellness, and OTC brands.

Top brands

-

Raw materials needed

Pharmaceutical raw materials sourced by contract manufacturers adhering to GMP standards.

Raw materials supplier

Contract manufacturers source verified raw materials; company does not own manufacturing plants.

Recurring vs cyclical contribution

Revenue driven by ongoing pharmaceutical product sales; largely recurring through sustained demand.

Our industry position

Emerging regional player expanding product range and geographic reach with robust contract manufacturing model.

Financial highlights

Fiscal 2025 revenue Rs 24.56 crore with net profit Rs 3.1 crore indicating steady growth.

Geographical revenue split

-

Order book

-

Whats driving growth

Expanding product portfolio, geographic reach, OTC segment entry, and strategic contract manufacturing partnerships.

Our future plans

Targeting pan-India presence via franchise model, launching 450+ products across 25+ therapeutic segments by 2030.

Our green promise

-

Our people and values

Over 20 years industry experience leadership, guided by quality, trustworthiness, hard work, and commitment core values.

Key challenges ahead

-

Interesting facts

Operates through 7 contract manufacturers with stringent quality checks and WHO-GMP certified partners.

Risks and strategy

-